Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) PT at $25.60

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have earned a consensus recommendation of “Buy” from the six brokerages that are covering the company, Marketbeat reports. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $25.60.

A number of analysts recently issued reports on the company. Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Tuesday, December 10th.

Astria Therapeutics Stock Up 1.2 %

ATXS opened at $9.56 on Thursday. Astria Therapeutics has a 52 week low of $5.94 and a 52 week high of $16.90. The firm has a 50-day simple moving average of $10.65 and a two-hundred day simple moving average of $10.69. The company has a market capitalization of $539.51 million, a PE ratio of -4.57 and a beta of 0.67.

Institutional Investors Weigh In On Astria Therapeutics

Large investors have recently modified their holdings of the business. Barclays PLC lifted its stake in shares of Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 38,321 shares during the period. Wellington Management Group LLP lifted its position in Astria Therapeutics by 8.7% during the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company’s stock worth $1,624,000 after acquiring an additional 11,763 shares during the period. RA Capital Management L.P. grew its stake in Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock valued at $56,208,000 after purchasing an additional 61,457 shares during the last quarter. Redmile Group LLC acquired a new position in shares of Astria Therapeutics in the third quarter valued at about $3,423,000. Finally, Patient Square Capital LP acquired a new stake in shares of Astria Therapeutics during the third quarter worth about $434,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.